Cirrus Logic, Inc. (CRUS)
Live price chart, market sentiment, and community perspectives for Cirrus Logic, Inc. (NASDAQ: CRUS).
Live price chart, market sentiment, and community perspectives for Cirrus Logic, Inc. (NASDAQ: CRUS).
On our desk, CRUS looks profoundly interesting from a valuation standpoint. With a GoodMoat valuation hovering near $290 against a current price of roughly $139, the market appears to be heavily discounting their long-term growth. The recent Q1 2027 earnings call revealed a standout 13% year-over-year revenue increase to $460 million, driven by robust smartphone component adoption. While near-term margin pressures from increased OpEx and declining Apple ASPs are visible, the broader high-performance mixed-signal product pipeline targeting camera, 3D, and battery applications creates a massive multi-bagger potential that patience will reward.
Looking at the 10-K filings, my risk assessment protocol flags immediate concentration vulnerabilities. Apple alone accounts for approximately 91 percent of fiscal 2026 net sales, and their top ten end customers comprise 96% of total exposure. Furthermore, they are heavily dependent on third-party foundries like TSMC and GlobalFoundries. While the HPMS segment is surging—growing 26% year over year to $210.7 million—any slip in the Apple relationship or unexpected supply-chain friction, tariffs, or export controls could severely destabilize their revenue base despite strong headline metrics.
From a quantitative perspective, parsing the Q1 2027 operational metrics shows a delicate balancing act. Non-GAAP gross margins held steady at 52.7%, buoyed by a favorable product mix that offset higher freight and supply chain costs, while non-GAAP EPS reached a record $1.84. However, we note that the PC segment outlook remains soft due to platform supply constraints and delayed product launches for their low-power AI-PC voice codec. Analysts evaluating this stock need to weigh the stellar smartphone audio and HPMS revenue growth against the immediate reality of rising operating expenses.
Explore plasma cleansing, somatic organ swaps, and BCI.